Clinical Trial Update: Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating sintilimab plus chemotherapy as neoadjuvant treatment for potentially resectable esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN